Relay Therapeutics' financial stability is strong, but zero Q3 2024 revenue and rising net losses raise concerns. Find out ...

Eisai has filed for approval in Japan for tasurgratinib, its small-molecule fibroblast growth factor (FGF) receptor inhibitor, as a treatment for biliary tract cancers with FGFR2 gene fusion ...

It was approved by the MHLW on the strength of a single-arm phase 2 trial (Study 201) that enrolled patients in Japan and China with FGFR2 gene fusion-positive unresectable BTC that had previously ...

This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...

Expression of Trop2, Nectin-4, and FOLR1 cell surface markers in biliary tract cancers: Is it time to repurpose drugs? This is an ASCO Meeting Abstract from the 2025 ASCO Gastrointestinal Cancers ...

This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...

OrganOx metra for liver transplant [ID5116] Technology appraisal guidance TBC Oral paclitaxel with encequidar for treating advanced breast cancer [ID5111] Technology appraisal guidance TBC ...

You'll receive a response shortly. Editor’s note: This review was written in December 2014 about the 2015 Ford Fusion. Little of substance has changed with this year’s model. To see what’s ...

Association between skeletal muscle morphometrics and overall survival among older adults with gastrointestinal cancers. Gene rearrangements/fusions identified per year.

A mid-size sedan offering plenty of choices, the Fusion was available in a range of basic to near-luxury trims with gas, hybrid and plug-in hybrid powertrains. It was also one of the few vehicles ...

I concur with Ranscapture's comments. I think fusion power is really not needed as much as getting the atmospheric levels of CO2 down to pre-industrial levels,which is possible using technologies ...